A systematic review of the budget impact analyses for antitumor drugs of lung cancer

Table 3 Quality evaluation of BIAs

First author	Perspective	Target population estimate	1–5 years of budget time horizon	Hypothetical scenario	Comparator	Frame description	Data collection and sources	Validation	Sensitivity analysis
Carlson [31]	√	√	√	√	√		√		√
Farsai [39]	√	√	√	√	√		√		√
Sumitra [40]	√	√	√	√	√	√	√		√
Preeti [32]	√	√	√	√	√	√	√		√
Lisa [33]	√	√	√	√	√	√	√	√
Mengyuan [41]	√	√	√	√	√	√	√		√
Sumitra [42]	√	√	√	√	√		√		√
Daniel [34]	√	√	√	√	√	√	√		√
Jan [43]	√	√	√	√	√	√	√	√	√
Pedro [44]	√	√	√				√
Christopher [35]	√	√	√	√	√	√	√		√
Jonathan [36]	√	√	√	√	√	√	√		√
Xueyan [45]	√	√	√	√	√	√	√		√
Jie [46]	√	√	√	√	√		√		√

ISSN: 1478-7547